Nkarta, Inc. Current Assets
Nkarta, Inc. (NKTX) had Current Assets of $188.04 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-10
- 2026-06-30: Assets, Current $188.04M.
- 2026-03-31: Assets, Current $235.88M.
- 2025-12-31: Assets, Current $282.51M.
- 2025-09-30: Assets, Current $289.27M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $188.04M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $235.88M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $282.51M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $289.27M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $296.57M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $271.55M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $273.34M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $290.15M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $331.80M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $442.78M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $253.07M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $281.19M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $286.74M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $332.19M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $360.69M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $400.92M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $417.38M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $223.22M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $245.78M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $264.64M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $283.94M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $302.23M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $318.83M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $333.39M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $22.30M 10-Q · filed 2020-08-20 | |
| 2019-12-31 | $37.47M 10-K · filed 2021-03-25 | $37.47M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |